Gastrointestinal blood loss in patients undergoing maintenance dialysis.
Gastrointestinal blood loss was measured for 14 days in 19 patients treated by hemodialysis and in 2 patients treated by chronic ambulatory peritoneal dialysis. 51Cr was used as a marker for erythrocytes. Fecal blood loss was 5.0 +/- 3.3 ml/day in hemodialysis patients who were not taking drugs affecting thrombocyte aggregation and 4.6 +/- 4.3 ml/day in those receiving sulfinpyrazone. There was no relationship between the severity of anemia, duration of dialysis, dose of heparin, grade of uremic intoxication, or dose of aluminum hydroxide and amount of fecal blood loss. It is concluded that gastrointestinal blood loss is not a major determinant of anemia in chronic renal failure. However, sulfinpyrazone is preferable to acetylsalicylic acid for prevention of shunt thrombosis in uremic patients because of their propensity for gastrointestinal bleeding.
D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008297:Male; D008551:Melena / Q000209:etiology* / Q000517:prevention & control; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D006435:Renal Dialysis / Q000009:adverse effects*; D013442:Sulfinpyrazone / Q000009:adverse effects / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control
D000536:Aluminum Hydroxide; D006493:Heparin; D013442:Sulfinpyrazone